1. Home
  2. JBGS vs DVAX Comparison

JBGS vs DVAX Comparison

Compare JBGS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBG SMITH Properties

JBGS

JBG SMITH Properties

HOLD

Current Price

$18.04

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.72

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBGS
DVAX
Founded
2016
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
JBGS
DVAX
Price
$18.04
$10.72
Analyst Decision
Sell
Buy
Analyst Count
2
4
Target Price
$16.50
$26.50
AVG Volume (30 Days)
722.3K
1.9M
Earning Date
10-28-2025
11-05-2025
Dividend Yield
3.89%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$501,226,000.00
$330,514,000.00
Revenue This Year
N/A
$23.23
Revenue Next Year
$1.79
$16.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.73
52 Week Low
$13.28
$9.20
52 Week High
$24.30
$14.63

Technical Indicators

Market Signals
Indicator
JBGS
DVAX
Relative Strength Index (RSI) 40.29 45.28
Support Level $17.36 $11.33
Resistance Level $18.69 $11.58
Average True Range (ATR) 0.58 0.34
MACD 0.14 -0.04
Stochastic Oscillator 60.69 0.00

Price Performance

Historical Comparison
JBGS
DVAX

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: